- **DT Cloud Acquisition Corporation (SPAC)**, Maius Pharmaceutical Co., Ltd., and Maius Pharmaceutical Group Co., Ltd. (PubCo) entered into a business combination agreement on **October 22, 2024**, which involves a SPAC Merger and an Acquisition Merger, ultimately resulting in PubCo becoming the parent company.  **[1944212_0001493152-25-016335_ex10-1.htm:0]** **[1944212_0001493152-25-016335_form8-k.htm:1]** 
- On **September 29, 2025**, the SPAC, Maius, and PubCo entered into a Subscription Agreement for a private placement, where an investor agreed to purchase **15,000 ordinary shares of PubCo** at a price of **$10.00 per share**.  **[1944212_0001493152-25-016335_form8-k.htm:1]** 
- DT Cloud Acquisition Corporation received a deficiency letter from Nasdaq on **September 25, 2025**, stating that its Market Value of Publicly Held Shares (MVPHS) has been below the minimum **$15 million requirement** for continued listing.  **[1944212_0001493152-25-016335_form8-k.htm:2]** 
- The company has **180 calendar days, until March 24, 2026**, to regain compliance with Nasdaq's MVPHS requirement.  **[1944212_0001493152-25-016335_form8-k.htm:2]**

DT Cloud Acquisition (DYCQ)